Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
Sponsor: West China Hospital
Summary
To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Official title: A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-03-01
Completion Date
2027-06-30
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
Topical application of Periplaneta americana-derived Meilian Fuxin Solution
A topical formulation derived from Periplaneta americana (Meilian Fuxin Solution).
Topical application of placebo
The placebo topical formulation will be composed of inactive ingredients and will be matched in appearance, texture, and administration regimen to the active Periplaneta americana-derived Meilian Fuxin Solution, and participants will also receive standard skin care for radiation dermatitis according to institutional clinical practice guidelines.
Radiotherapy
One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
Locations (2)
Sichuan University West China Hospital, Chengdu, Sichuan
Chengdu, Sichuan, China
Sichuan University West China Hospital
Chengdu, Sichuan, China